View ValuationVireo Growth 将来の成長Future 基準チェック /56Vireo Growth収益と収益がそれぞれ年間164.4%と24%増加すると予測されています。主要情報164.4%収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.3%収益成長率24.0%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日20 Aug 2026今後の成長に関する最新情報Price Target Changed • Jan 13Price target decreased to CA$0.85Down from CA$1.00, the current price target is provided by 1 analyst. New target price is 270% above last closing price of CA$0.23. The company posted a net loss per share of US$0.27 last year.すべての更新を表示Recent updatesお知らせ • Aug 22Vireo Growth Inc. (CNSX:VREO) completed the acquisition of C21 Investments Inc. (CNSX:CXXI).Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $35.7 million on June 14, 2026. Vireo agreed to acquire all of the issued and outstanding common shares (collectively, the “C21 Shares”) after exchange of all subordinate voting shares of C21 into C21 Shares. Under the Arrangement, each issued and outstanding subordinate voting share of C21 (other than any C21 Share held by a dissenting shareholder) will be exchanged for 0.000001 common shares of C21. Following such exchange, each C21 common share outstanding will be transferred to Vireo in exchange for 0.023052 subordinate voting shares of Vireo. Subject to the satisfaction of all conditions to closing, upon completion of the Transaction, it is expected that the C21 Shares will be delisted from the Canadian Securities Exchange and the OTCQX Market and that C21 will apply to cease to be a reporting issuer under applicable Canadian and U.S. securities laws. In case of termination of transaction, seller will pay a termination fee of $3 million. The transaction is subject to subject to court approval, approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board and approval of offer by target shareholders. The Board of Directors of C21 Investments Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board. The special meeting for the shareholders of C21 Investments will be held to approve the transaction on August 7, 2026. The transaction is expected to close in the third quarter of 2026. On August 7, 2026, shareholders of C21 approved the transaction. C21 plans to apply for a final order of the Supreme Court of British Columbia for approval of the Arrangement on August 13, 2026. Assuming the satisfaction or waiver of other customary closing conditions and subject to the receipt of all relevant regulatory and court approvals, the transaction is expected to close on or about August 21, 2026. Needham & Company, LLC is acting as financial advisor to the C21 Board and provided the Independent Fairness Opinion to the C21 Board. Mikhail Ilinets and Amy Laverdure of Koffman Kalef LLP and Dorsey & Whitney LLP acted as legal advisor for C21 Investments Inc. Derek Bell, Russel Drew and Jamie Mandell of DLA Piper LLP acted as legal advisor for Vireo Growth Inc. Matthew Block and Craig Alcorn of Eversheds Sutherland LLP acted as legal advisor for Vireo Growth Inc. Computershare Investor Services Inc. acted as transfer agent for C21 Investments Inc. Davidson & Company LLP acted as accountant for C21 Investments Inc. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of C21 Investments Inc. (CNSX:CXXI) on August 21, 2026.New Risk • Aug 20New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$118m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$118m free cash flow). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding).New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Minor Risk Less than 1 year of cash runway based on current free cash flow (-US$118m).Reported Earnings • Aug 11Second quarter 2026 earnings released: US$0.002 loss per share (vs US$0.80 loss in 2Q 2025)Second quarter 2026 results: US$0.002 loss per share (improved from US$0.80 loss in 2Q 2025). Revenue: US$209.3m (up 336% from 2Q 2025). Net loss: US$100.0k (loss narrowed 99% from 2Q 2025). Profit margin: 0% (up from net loss in 2Q 2025). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 42% per year whereas the company’s share price has increased by 45% per year.お知らせ • Aug 08Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Certain retail assets and properties of PharmaCann Inc.Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for approximately $49 million on December 16, 2025. Total consideration is payable in subordinate voting shares of the Vireo Growth, as well as the assumption of certain liabilities. On March 22, 2026, a Management Services Agreement (MSA) became effective, allowing an affiliate of Vireo to manage the assets in the interim. On the same date, 90,740,741 subordinate voting shares were delivered into escrow pending the close of the acquisition. The transaction is expected to close in the second fiscal quarter of 2026, subject to regulatory approval. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Certain retail assets and properties of PharmaCann Inc. on August 7, 2026.Total consideration for the acquired assets was approximately $49.0 million, consisting of the issuance of Vireo subordinate voting shares and the assumption of certain liabilities. The final share consideration reflects customary closing adjustments, including inventory levels, trade payables and other items as provided for in the Asset Purchase Agreement. The acquired business includes 17 dispensaries.お知らせ • Aug 04Vireo Growth Inc. to Report Q2, 2026 Results on Aug 11, 2026Vireo Growth Inc. announced that they will report Q2, 2026 results Pre-Market on Aug 11, 2026お知らせ • Aug 01Vireo Growth Inc. (CNSX:VREO) entered into a definitive securities purchase agreement to acquire FARMACEUTICALRX LLC.Vireo Growth Inc. (CNSX:VREO) entered into a definitive securities purchase agreement to acquire FARMACEUTICALRX LLC on July 31, 2026. In a separate related transactions, Vireo Growth Inc. entered into a definitive securities purchase agreements to acquire FarmaceuticalRx 2 LLC, CAOH LLC, and Canoe Hill Ohio, LLC on July 31, 2026. Collectively, the acquired businesses include eight dispensaries, a cultivation and processing facility, and related owned and leased real estate, establishing a vertically integrated operating platform in Ohio. Subject to customary adjustments for cash, debt, pre-closing taxes and transaction expenses, the aggregate purchase price across all four acquisitions is expected to be approximately $208 million, which will be satisfied by issuing approximately 11 million subordinate voting shares of Vireo. The subordinate voting shares will be issued in three tranches, with 50% of the consideration issued at closing, 25% approximately 90 days following closing, and the remaining 25% approximately 180 days following closing. The deferred consideration in each Ohio Transaction is subject to the continued performance of the acquired businesses and a forfeiture mechanism entitling Vireo to claw back up to 25% of the subordinate voting shares issued to the various Sellers if specified performance thresholds and other conditions specified in the purchase agreements are not met during the applicable measurement periods. Following the completion of the Ohio Transactions, the Ohio Entities and their subsidiaries will join Vireo’s growing cannabis segment. The transaction is subject to the receipt of all required regulatory approvals and the satisfaction of certain other closing conditions customary in transactions of this nature. Closing is expected to occur in Q4 2026, subject to the satisfaction of all closing conditions.お知らせ • Jul 28Vireo Growth Inc. (CNSX:VREO) entered into a definitive merger agreement to acquire Planet 13 Holdings Inc. (CNSX:PLTH) for $51.9 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive merger agreement to acquire Planet 13 Holdings Inc. (CNSX:PLTH) for $51.9 million on July 26, 2026. Under the terms of the agreement, each issued and outstanding share of common stock of Planet 13 will be converted into the right to receive 0.015 of a Vireo subordinate voting share. The price represents a 16.6% premium over Planet 13’s 20-day volume weighted average price per share as of July 24, 2026, the last trading day before the execution of the Merger Agreement. In case of termination of transaction, Planet 13 Holdings will pay a termination fee of $1.80 million. The transaction is subject to closing conditions, including obtaining Planet 13 stockholder approval, the effectiveness of a registration statement on Form S-4 to be filed with the U.S. Securities and Exchange Commission, approval of the listing of the Vireo shares issuable in the Transaction by the Canadian Securities Exchange, and applicable cannabis regulatory approvals. The Board of Directors of Planet 13 Holdings Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board of both companies. Upon completion of the transaction, it is expected that the Planet 13 shares of common stock will be delisted from the Canadian Securities Exchange and withdrawn from the OTCQX Market and that Planet 13 will apply to cease to be a reporting issuer under applicable United States and Canadian securities laws. ATB Cormark Capital Markets acted as financial advisor and fairness opinion provider to the Special Committee. Eversheds Sutherland (US) LLP and DLA Piper (Canada) LLP acted as legal advisors to Vireo. Cozen O’Connor is serving as legal advisor to Planet 13. Foley Hoag LLP is serving as legal advisor to the Special Committeeお知らせ • Jul 18Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC acquired FarmX, LLC.Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC entered into a Securities Purchase Agreement to acquire FarmX, LLC for $20 million on July 2, 2026. The total consideration consists of $8 million in cash payable at closing and $12 million payable through the issuance of approximately 645,161 subordinate voting shares of Vireo. The stock consideration is scheduled to be issued two years following the closing date. Post-transaction, the acquired permit will allow Vive Penn, LLC to operate up to six retail medical dispensaries in Pennsylvania. The transaction is subject to approval by regulatory board / committee and customary closing conditions. The transaction is expected to close two business days following the date the parties satisfy all conditions precedent to the agreement. Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC completed the acquisition of FarmX, LLC on July 17, 2026.お知らせ • Jun 17Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million on June 15, 2026. The consideration consists of 2.72 million common equity of Vireo Growth Inc. at a ratio of 0.023052 per common equity of C21 Investments Inc. As part of consideration, an undisclosed value is paid towards common equity of C21 Investments Inc. In case of termination of transaction, seller will pay a termination fee of $3 million. The transaction is subject to subject to court approval, approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board and approval of offer by target shareholders. The Board of Directors of C21 Investments Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board. The transaction is expected to close in the third quarter of 2026. Needham & Company, LLC acted as fairness opinion provider and Koffman Kalef LLP, Dorsey & Whitney LLP and DLA Piper LLP acted as legal advisors for C21 Investments Inc. Eversheds Sutherland LLP acted as legal advisor for Vireo Growth Inc.Buy Or Sell Opportunity • Jun 04Now 232% overvalued after recent price riseOver the last 90 days, the stock has risen 2,800% to CA$17.40. The fair value is estimated to be CA$5.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last 3 years. Earnings per share has grown by 40%.お知らせ • May 26Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million.Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million on May 25, 2026. The consideration consists of convertible debt of Vireo Growth Inc. having a value of $10.26 million to be issued for common equity of Bridgewell Agribusiness LLC. The aggregate consideration for the Bridgewell Transaction is based on a base purchase price of US$40 million, subject to adjustments for, among other things, approximately US$30 million of assumed indebtedness of Bridgewell that will remain outstanding following closing and the assumption of certain other transaction expenses. After giving effect to such adjustments, the estimated closing purchase price is expected to be approximately US$10.26 million In exchange for the issued and outstanding membership interests of Bridgewell, Vireo will issue an unsecured, subordinated convertible note to the Seller (the “Convertible Note”) in the aggregate principal amount equal to the closing purchase price, which will automatically convert on or after the second anniversary of closing into an estimated 16,552,150 subordinate voting shares of Vireo (the “Consideration Shares”) at a deemed price of US$0.62 per Consideration Share (which final price will be subject to the policies of the Canadian Securities Exchange and based on the volume weighted average trading price of the Company’s subordinate voting shares for 20 consecutive trading days ending two trading days prior to the closing date). The aggregate principal amount of the Convertible Note and number of Consideration Shares issuable thereunder are subject to certain post-closing purchase price and other adjustments. The transaction is subject to approval by regulatory board / committee and definitive agreement. The Bridgewell Transaction could close any time following five (5) business days.Reported Earnings • May 13First quarter 2026 earnings released: US$0.019 loss per share (vs US$0.018 loss in 1Q 2025)First quarter 2026 results: US$0.019 loss per share (further deteriorated from US$0.018 loss in 1Q 2025). Revenue: US$106.2m (up 333% from 1Q 2025). Net loss: US$20.3m (loss widened 212% from 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.お知らせ • May 07Vireo Growth Inc. to Report Q1, 2026 Results on May 12, 2026Vireo Growth Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026お知らせ • May 02Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million on April 30, 2026. As part of the acquisition, Vireo Growth Inc. will acquire all of the issued and outstanding common shares of FLUENT Corp. As part of consideration, each shareholder of FLUENT Corp will receive 0.0705359 of a subordinate voting share of Vireo Growth Inc in exchange for each FLUENT Corp Share held. Following the completion of the Transaction, FLUENT will join the Vireo ecosystem and gain exposure to a larger and well capitalized multi-state operator currently operating in 10 states across the U.S. In connection with the Transaction, Vireo has entered into voting support agreements with certain directors, officers and key shareholders of FLUENT, with such holders representing approximately 38.3% of the issued and outstanding FLUENT Shares, pursuant to which they have agreed to, among other things, vote their FLUENT Shares in favor of the Transaction. Chris Hagedorn has resigned from the FLUENT Board. The vacancy will not be filled at this time. Upon completion, it is expected that the FLUENT Shares will be delisted from the Canadian Securities Exchange (“CSE”) and the OTCQB Venture Market and that FLUENT will apply to cease to be a reporting issuer under applicable Canadian securities laws. In case of termination of transaction, FLUENT Corp. will pay a termination fee of $2 million to Vireo Growth Inc. The transaction is subject to court approvals, as well as the receipt of all required regulatory approvals, the completion of the Equitization, and the satisfaction of certain other closing conditions customary in transactions of this nature, approval by the shareholders of FLUENT Corp and other third-party approvals. The Board of Directors of FLUENT Corp. formed a special committee for the transaction. The Special Committee and the FLUENT Board have unanimously determined that the Transaction is in the best interests of FLUENT and is fair to the FLUENT Shareholders and the FLUENT Board recommends that the FLUENT Shareholders vote in favor of the Transaction. The transaction is expected to close in the fourth quarter of 2026. ATB Cormark Capital Markets acted as fairness opinion provider to the Special Committee and board of directors of FLUENT Corp. ATB Cormark Capital Markets acted as financial advisor to the Special Committee of FLUENT Corp. Cassels Brock & Blackwell LLP acted as legal advisor to FLUENT Corp. Goodwin Procter LLP acted as legal advisor to FLUENT Corp. DLA Piper (Canada) LLP acted as legal advisor to Vireo Growth Inc. Eversheds Sutherland (US) LLP acted as legal advisor to Vireo Growth Inc. Shenker Russo & Clark LLP acted as legal advisor to Vireo Growth Inc. Foley & Lardner LLP acted as legal advisor to Vireo Growth Inc.お知らせ • Apr 17Vireo Growth Inc. announced that it has received $50.612571 million in fundingOn April 16, 2026. Vireo Growth Inc. announced that it has closed the transaction.お知らせ • Apr 09Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million.Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. for approximately $120 million on January 15, 2026. As part of consideration Vireo Growth Inc. issued 206 million ordinary shares, a warrant to purchase 80 million at an exercise price of $0.85 per Share, exercisable for a period of five years from the date of issuance. Additional Vireo Growth Inc. acquire The Hawthorne Gardening Company $35 million of cash, approximately $50 million of net working capital, and would be provided approximately $20 million of inventory. Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors upon completion of the transition upon completion of the transaction and shareholder approval. The transaction is subjected to regulatory approvals and the finalization of a definitive agreement. If applicable, the approval of the Canadian Securities Exchange. The expected to be completed during the second quarter of 2026. Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million on April 8, 2026. Under the terms of the transaction, Vireo Growth Inc. acquired $35 million of cash held by Hawthorne, and issued 213 million of its subordinate voting shares and a warrant to purchase 80 million at an exercise price of $0.85 per Share.お知らせ • Apr 01Vireo Growth Inc. Announces Cory Azzalino to Step into the CEO Role of Vireo’s California BusinessVireo Growth Inc. announced Cory Azzalino will step into the CEO role of Vireo’s California business – Cory and his team bring operational acumen and emphasis on retail excellence which strengthens Vireo’s platform.Reported Earnings • Mar 18Full year 2025 earnings released: US$0.093 loss per share (vs US$0.15 loss in FY 2024)Full year 2025 results: US$0.093 loss per share. Revenue: US$268.8m (up 170% from FY 2024). Net loss: US$68.1m (loss widened 143% from FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Mar 17Vireo Growth Inc., Annual General Meeting, May 29, 2026Vireo Growth Inc., Annual General Meeting, May 29, 2026.お知らせ • Mar 10Vireo Growth Inc. to Report Q4, 2025 Results on Mar 17, 2026Vireo Growth Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 17, 2026お知らせ • Jan 28Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding Memorandum of Understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc.Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. on January 28, 2026. Upon completion, Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors.Recent Insider Transactions Derivative • Jan 02President exercised options and sold CA$104k worth of stockOn the 29th of December, Amber Shimpa exercised options to acquire 127k shares at no cost and sold these for an average price of CA$0.82 per share. This trade did not impact their existing holding. Since March 2025, Amber's direct individual holding has increased from 875.63k shares to 1.97m. This was the only transaction from an insider over the last 12 months.分析記事 • Dec 30Vireo Growth Inc.'s (CSE:VREO) 38% Jump Shows Its Popularity With InvestorsVireo Growth Inc. ( CSE:VREO ) shareholders are no doubt pleased to see that the share price has bounced 38% in the...お知らせ • Dec 23Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million.Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million on December 22, 2025. The consideration is payable through the issuance of approximately 84 million subordinate voting shares of the Vireo at closing. Total consideration payable in the transaction will be subject to adjustment based on closing levels of cash, indebtedness, tax obligations and working capital adjustments, as well as the occurrence of certain other events by the closing date. Eaze may be entitled to earn-out consideration as of December 31, 2026. Eaze will become a wholly-owned subsidiary of Vireo. The expected completion of the transaction is January 1, 2026 to June 30, 2026.お知らせ • Dec 18Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million.Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million on December 16, 2025. Total consideration is payable in subordinate voting shares of the Vireo Growth, as well as the assumption of certain liabilities. The transaction is subject to satisfaction of closing conditions and state and local regulatory approvals. The transaction is expected to close during the first half of calendar year 2026.分析記事 • Nov 15With A 35% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay ForThe Vireo Growth Inc. ( CSE:VREO ) share price has fared very poorly over the last month, falling by a substantial 35...New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 1.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 1.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (362% increase in shares outstanding).Reported Earnings • Nov 14Third quarter 2025 earnings released: US$0.042 loss per share (vs US$0.024 loss in 3Q 2024)Third quarter 2025 results: US$0.042 loss per share (further deteriorated from US$0.024 loss in 3Q 2024). Revenue: US$91.7m (up 264% from 3Q 2024). Net loss: US$26.3m (loss widened 434% from 3Q 2024). Revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 31Vireo Growth Inc. to Report Q3, 2025 Results on Nov 12, 2025Vireo Growth Inc. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025お知らせ • Oct 29Vireo Growth Inc. and Verano Holdings Corp. Reaches Comprehensive Settlement Dismissing All Outstanding Litigation MattersVireo Growth Inc. and Verano Holdings Corp. on October 29, 2025 announced that they have reached a comprehensive settlement dismissing all outstanding litigation matters between the two Companies that are pending before the Supreme Court of British Columbia, Canada. The terms of the Settlement Agreement were approved by the respective Boards of Directors of both Companies. The value of the settlement to Vireo is approximately USD 10 million consisting of the acquisition of certain real estate assets and USD 1 million in cash. The resolution marks the conclusion of a complex legal chapter and reflects a commitment by both Companies to move forward in a constructive manner. Both Companies reiterated their dedication to delivering long-term value to their shareholders and quality products and services to their customers.お知らせ • Oct 24Vireo Growth Inc. announced that it has received $61.996221 million in fundingOn October 23, 2025, Vireo Growth Inc closed the transaction. The transaction included participation from 22 investors.お知らせ • Sep 16Vireo Growth Inc. Announces Launch of Adult-Use Cannabis Sales in MinnesotaVireo Growth Inc. announced that on September 16, 2025, it recorded its first sale of adult use cannabis in Minnesota at its historic downtown Minneapolis Green Goods® dispensary. The Company is now dispensing a full suite of both medical and adult-use cannabis products at all eight of its Green Goods™ dispensaries located throughout the State of Minnesota. Vireo has been operating in Minnesota’s medical cannabis market since 2014, serving tens of thousands of patients with safe, reliable products. The Company is committed to expanding access, improving product quality, and supporting the state’s transition to a sustainable, locally driven adult-use market. As one of the state’s operational licensed adult-use cannabis cultivators and retailers, and a population of 5.7 million people, the launch of Minnesota’s adult-use cannabis market is expected to serve as a strong organic revenue growth catalyst for Vireo for the foreseeable future. Green Goods® offers a full suite of medical and adult-use cannabis products and form factors including flower, pre-rolls, edibles, and beverages, and currently operates eight retail dispensaries in Minnesota. Green Goods® dispensaries are located in Minneapolis, Blaine, Bloomington, Burnsville, Duluth, Moorhead, Rochester, and Woodbury. For more information about Green Goods or to shop its product menu, please visit www.visitgreengoods.com.分析記事 • Sep 11With A 33% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay ForVireo Growth Inc. ( CSE:VREO ) shares have retraced a considerable 33% in the last month, reversing a fair amount of...Reported Earnings • Aug 14Second quarter 2025 earnings released: US$0.027 loss per share (vs US$0.005 loss in 2Q 2024)Second quarter 2025 results: US$0.027 loss per share (further deteriorated from US$0.005 loss in 2Q 2024). Revenue: US$48.1m (up 91% from 2Q 2024). Net loss: US$14.9m (loss widened US$14.3m from 2Q 2024). Revenue is forecast to grow 78% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Aug 05Vireo Growth Inc. to Report Q2, 2025 Results on Aug 13, 2025Vireo Growth Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 13, 2025お知らせ • Jul 10Vireo Growth Inc. announced that it has received $10 million in funding from Chicago Atlantic Opportunity Finance, LLCVireo Growth Inc announced that it has completed a private placement and issued $10,000,000 principal amount of convertible Notes on July 9, 2025. The Notes are convertible into an aggregate of 16,000,000 Shares upon exercise. The new convertible note was issued in reliance upon exemptions from the registration requirements of the U.S. Securities Act of 1933, as amended and applicable Canadian and U.S state Securities laws. The transaction included participation from Chicago Atlantic Opportunity Finance, LLC.お知らせ • Jun 10Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million.Vireo Growth Inc. (CNSX:VREO) has signed definitive agreement to acquire Deep Roots Harvest, Inc. on December 18, 2024. Total consideration is approximately $397 million of all-stock transactions. In Related transactions Vireo has signed definitive agreements to acquire Proper Brands in Missouri and WholesomeCo Cannabis in Utah, while also signing a binding MOU to acquire The Flowery in Florida. Vireo estimates proforma revenue and EBITDA of the combined company of approximately $394 million and $94 million, respectively, for calendar year 2024. Upon closing of the Merger Transactions, Vireo estimates the combined company will be well-positioned for further growth with a favorable balance sheet consisting of approximately $99 million of cash and $78 million of net debt with an EBITDA leverage ratio of approximately 0.8x. The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. The Deep Roots Merger Agreement also contains customary indemnification obligations of Vireo and Deep Roots, other obligations of the parties and termination provisions, under which, subject to certain conditions and in certain instances of termination, would require Vireo or Deep Roots to pay a termination fee equal to $6.37624 million. These acquisition targets may qualify for earnout payments on December 31, 2026, based on 4x EBITDA growth compared to Reference EBITDA, adjusted for incremental debt, and paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. Reference EBITDA for Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are $31.0 million, $31.0 million, and $16.0 million, respectively. John Mazarakis, co-founder at Chicago Atlantic, has been appointed to the role of Chief Executive Officer and Co-Executive Chairman, effective immediately. Tyson Macdonald, former partner at TrueRise Capital, has been appointed to the role of Chief Financial Officer, effective immediately. Amber Shimpa will continue to serve as President of the Company and as Chief Executive Officer of Minnesota, Maryland, and New York. Implementation of the Merger Transactions are subject to the approval of holders of a majority of Vireo's voting shares and regulatory approvals. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and each of the target acquisition companies. Vireo anticipates that closing of all of the Merger Transactions to take at least six months pending shareholder and regulatory approvals. Vireo expects that each transaction will be accretive to the broader portfolio. Moelis & Company LLC acted as fairness opinion provider for Boards of Directors of Vireo Growth Inc. Moelis & Company LLC acted as financial advisor for Vireo Growth Inc. Dorsey & Whitney LLP acted as legal advisor for Vireo Growth Inc. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million on June 9, 2025. Total consideration for the transaction is paid in the form of 255.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52. The purchase price of the Deep Roots transaction represents a multiple of 4.175x 2024 “Closing EBITDA” of $30 million.お知らせ • Jun 06Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands on December 18, 2024. Under the terms of the transaction, the transaction is expected to be effected by way of an all-stock transaction, and The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. Reference EBITDA for Proper Brands is $31.0 million. Vireo will include in the stock merger consideration calculation an amount equal to $2,139,200 for the stockholders of Proper Brands for all of the outstanding equity interests in Arches IP, Inc. owned by Proper Brands with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The seller of Proper Brand has agreed to voluntary share lock-up after 33 months of consummation. In separate transactions, Vireo will also acquire Deep Roots Harvest, WholesomeCo Cannabis, and The Flowery. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board, subject to shareholder approval and lock-up agreement, and a clawback provision if they perform below the respective Reference EBITDA measured as the higher of trailing twelve-months or nine-months annualized EBITDA as of December 31, 2026, adjusted for any intercompany funding. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and Proper Brands. In certain instances of termination, Vireo or Proper Brands is required to pay a termination fee equal to $4,631,012. Moelis & Company LLC acted as financial advisor and Fairness Opinion Provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million on June 5, 2025. Total consideration for the transactions was $102 million, paid in the form of 196.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52.お知らせ • May 13Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis.Vireo Growth Inc. (CNSX:VREO) signed an agreement to acquire WholesomeCo Cannabis on December 18, 2024. Vireo has signed three definitive documents and one binding Memorandum of Understanding to acquire four single-state operators (Proper Brands, Deep Roots Harvest, and Bill’s Nursery, Inc, WholesomeCo Cannabis) for total consideration of approximately $397 million in a series of all-stock transactions and may qualify for earnout payments on December 31, 2026. Vireo will include in the stock merger consideration calculation an amount equal to $11,860,800 for the stockholders of WholesomeCo Cannabis for all of the outstanding equity interests in Arches IP, Inc. owned by WholesomeCo Cannabis with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The transaction is subject to certain shareholder and regulatory approvals, and clawback provision. In certain instances of termination, Vireo or WholesomeCo Cannabis is required to pay a termination fee equal to $3,394,217. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and WholesomeCo Cannabis. As of March 9, 2025, Vireo Growth Inc. has obtained required regulatory approvals and is working toward satisfying all other customary closing conditions, which it expects to meet during the second quarter of 2025. Moelis & Company LLC acted as financial advisor and fairness opinion provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing. Adam Hull of Polsinelli PC acted as legal advisor to WholesomeCo. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis for $69.8 million on May 12, 2025. $69.8 million paid in the form of 134.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52.Reported Earnings • May 10First quarter 2025 earnings released: US$0.018 loss per share (vs US$0.047 loss in 1Q 2024)First quarter 2025 results: US$0.018 loss per share (improved from US$0.047 loss in 1Q 2024). Revenue: US$24.5m (up 1.9% from 1Q 2024). Net loss: US$6.51m (loss narrowed 3.0% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • Apr 29Vireo Growth Inc. to Report Q1, 2025 Results on May 09, 2025Vireo Growth Inc. announced that they will report Q1, 2025 results Pre-Market on May 09, 2025お知らせ • Apr 09Vireo Growth Inc., Annual General Meeting, Jun 20, 2025Vireo Growth Inc., Annual General Meeting, Jun 20, 2025.分析記事 • Apr 04Revenues Not Telling The Story For Vireo Growth Inc. (CSE:VREO) After Shares Rise 26%Vireo Growth Inc. ( CSE:VREO ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...分析記事 • Mar 31Is Vireo Growth (CSE:VREO) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Reported Earnings • Mar 04Full year 2024 earnings released: US$0.15 loss per share (vs US$0.19 loss in FY 2023)Full year 2024 results: US$0.15 loss per share. Revenue: US$99.4m (up 13% from FY 2023). Net loss: US$28.0m (loss widened 9.6% from FY 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Feb 20Vireo Growth Inc. to Report Q4, 2024 Results on Mar 04, 2025Vireo Growth Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025お知らせ • Jan 01Vireo Growth Inc. announced that it has received $80.960546 million in fundingOn December 30, 2024, Vireo Growth Inc., closed the transaction. The company issued 129,536,874 subordinate voting shares at a price of $0.625 per share for the gross proceeds of $80,960,546.25 in the transaction. The transaction has been oversubscribed.お知らせ • Dec 19+ 4 more updatesVireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands on December 18, 2024. Under the terms of the transaction, the transaction is expected to be effected by way of an all-stock transaction, and The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. These acquisition targets may qualify for earnout payments on December 31, 2026, based on 4x EBITDA growth compared to Reference EBITDA, adjusted for incremental debt, and paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. Reference EBITDA for Proper Brands is$31.0 million. Total payment for Arches includes $14 million in upfront consideration to WholesomeCo and Proper Brands with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The seller of Bill's Nursery has agreed to voluntary share lock-up after 33 months of consummation. In separate transactions, Vireo will also acquire Deep Roots Harvest, WholesomeCo Cannabis, and The Flowery. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board, subject to shareholder approval and lock-up agreement, and a clawback provision if they perform below the respective Reference EBITDA measured as the higher of trailing twelve-months or nine-months annualized EBITDA as of December 31, 2026, adjusted for any intercompany funding. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and Bill's Nursery. Moelis & Company LLC acted as financial advisor and Fairness Opinion Provider, and Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing.分析記事 • Nov 27Risks Still Elevated At These Prices As Vireo Growth Inc. (CSE:VREO) Shares Dive 26%Vireo Growth Inc. ( CSE:VREO ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Reported Earnings • Nov 15Third quarter 2024 earnings released: US$0.024 loss per share (vs US$0.037 loss in 3Q 2023)Third quarter 2024 results: US$0.024 loss per share (improved from US$0.037 loss in 3Q 2023). Revenue: US$25.2m (up 2.0% from 3Q 2023). Net loss: US$4.93m (loss narrowed 5.8% from 3Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.お知らせ • Nov 05Vireo Growth Inc. announced that it expects to receive $10 million in fundingVireo Growth Inc. announced that it has secured a new convertible debt facility which provides a financing commitment of up to $10,000,000 in aggregate principal amount of convertible notes on November 4, 2024. This facility is being funded by the Company’s senior secured lender and its affiliates under the Company’s existing credit agreement. The convertible facility has a term of three years, with a cash interest rate of 12.0 percent, and such interest shall be paid to Lender in cash on the last business day of each calendar month. The Convertible Notes shall be convertible at any time into Subordinate Voting Shares of the Company, at the option of Lender, in whole but not in part, in a single transaction, at a conversion price equal to $0.625.お知らせ • Oct 30Vireo Growth Inc. to Report Q3, 2024 Results on Nov 13, 2024Vireo Growth Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: CA$110.5m (US$80.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Market cap is less than US$100m (CA$110.5m market cap, or US$80.3m).分析記事 • Oct 12Vireo Growth Inc.'s (CSE:VREO) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatioVireo Growth Inc. ( CSE:VREO ) shares have had a horrible month, losing 29% after a relatively good period beforehand...お知らせ • Oct 11+ 1 more updateVireo Growth Inc. Announces CFO ChangesVireo Growth Inc. announced several leadership updates. Josh Rosen has resigned from the Company's interim Chief Financial Officer, effective immediately, to focus on his other business ventures. Mr. Rosen was first elected to the Board in August 2021, and appointed to executive leadership roles in November 2022, including, most recently, the roles of Chief Executive Officer and interim Chief Financial Officer. The Company has engaged Mr. Rosen going forward with a consulting agreement. Joe Duxbury has been appointed as Interim Chief Financial Officer while the Company searches for a permanent replacement. Mr. Duxbury has been with the Company since 2019 in financial and accounting roles of increasing responsibility, and most recently was serving as Vice President of Finance leading external reporting and investor relations.お知らせ • Oct 10Vireo Growth Inc. Announces Resignation of Josh Rosen as DirectorVireo Growth Inc. announced several leadership updates. Josh Rosen has resigned from the Company's Board of Directors, effective immediately, to focus on his other business ventures. Mr. Rosen was first elected to the Board in August 2021, and appointed to executive leadership roles in November 2022, including, most recently, the roles of Chief Executive Officer and interim Chief Financial Officer. The Company has engaged Mr. Rosen going forward with a consulting agreement.Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. CEO, Interim CFO & Director Josh Rosen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Aug 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).お知らせ • Aug 20Vireo Growth Inc. announced that it has received $5.3875 million in fundingOn August 20, 2024, Vireo Growth Inc. closed the transaction. The transaction included participation from 14 investors.分析記事 • Aug 10Vireo Growth Inc. (CSE:VREO) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedVireo Growth Inc. ( CSE:VREO ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.057 loss in 2Q 2023)Second quarter 2024 results: US$0.005 loss per share (improved from US$0.057 loss in 2Q 2023). Revenue: US$25.1m (up 24% from 2Q 2023). Net loss: US$668.4k (loss narrowed 91% from 2Q 2023). Revenue is expected to decline by 1.4% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Canada are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.お知らせ • Jul 23Vireo Growth Inc. to Report Q2, 2024 Results on Aug 06, 2024Vireo Growth Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024分析記事 • Jun 01Market Might Still Lack Some Conviction On Goodness Growth Holdings, Inc. (CSE:GDNS) Even After 30% Share Price BoostGoodness Growth Holdings, Inc. ( CSE:GDNS ) shares have continued their recent momentum with a 30% gain in the last...お知らせ • May 31Goodness Growth Holdings, Inc. announced that it expects to receive $0.7 million in fundingGoodness Growth Holdings, Inc. announced a non-brokered private placement of its subordinate voting shares for the gross proceeds of $700,000 on May 30, 2024. The company expects that this transaction will be completed within the next five business days. All of the subordinate voting shares issued in connection with this private placement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.Reported Earnings • May 08First quarter 2024 earnings released: US$0.047 loss per share (vs US$0.066 loss in 1Q 2023)First quarter 2024 results: US$0.047 loss per share (improved from US$0.066 loss in 1Q 2023). Revenue: US$24.1m (up 26% from 1Q 2023). Net loss: US$6.71m (loss narrowed 20% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.お知らせ • May 03+ 1 more updateGoodness Growth Holdings, Inc. Appoints Josh Rosen as Chief Executive OfficerGoodness Growth Holdings, Inc. announced several leadership and corporate updates related to the day-to-day management of its business. Josh Rosen, who has served as Interim CEO since February of 2023, has been appointed as Chief Executive Officer, effective immediately. Josh Rosen’s leadership over the course of the past 14 months has been instrumental in securing a path forward for Company as a standalone enterprise. The company have been immensely impressed with Josh’s stewardship of the organization through the exceptionally challenging circumstances that were created by Verano’s wrongful termination of merger agreement. During his tenure as Interim CEO, he has significantly improved fundamental operating and financial performance, and has represented the Company admirably in his interactions with both internal and external stakeholders.お知らせ • May 01Goodness Growth Holdings, Inc. to Report Q1, 2024 Results on May 07, 2024Goodness Growth Holdings, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024お知らせ • Apr 13Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024.分析記事 • Apr 06Goodness Growth Holdings, Inc. (CSE:GDNS) Stock Rockets 30% But Many Are Still Ignoring The CompanyDespite an already strong run, Goodness Growth Holdings, Inc. ( CSE:GDNS ) shares have been powering on, with a gain of...お知らせ • Apr 03Goodness Growth Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023Goodness Growth Holdings, Inc. reported impairment charges for the fourth quarter ended December 31, 2023. For the period, the company reported loss on impairment of long-lived assets of USD 411,629 compared to USD 1,119,583 last year same period.Reported Earnings • Apr 02Full year 2023 earnings released: US$0.19 loss per share (vs US$0.33 loss in FY 2022)Full year 2023 results: US$0.19 loss per share (improved from US$0.33 loss in FY 2022). Revenue: US$88.1m (up 18% from FY 2022). Net loss: US$25.5m (loss narrowed 40% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 15Goodness Growth Holdings, Inc. to Report Q4, 2023 Results on Mar 28, 2024Goodness Growth Holdings, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 28, 2024分析記事 • Feb 01Investors Still Aren't Entirely Convinced By Goodness Growth Holdings, Inc.'s (CSE:GDNS) Revenues Despite 59% Price JumpGoodness Growth Holdings, Inc. ( CSE:GDNS ) shares have continued their recent momentum with a 59% gain in the last...お知らせ • Dec 15Goodness Growth Holdings, Inc. Announces Departure of Michael Schroeder as General Counsel & Chief Compliance Officer Effective December 15, 2023Goodness Growth Holdings, Inc. announced that the Company’s General Counsel and Chief Compliance Officer, Michael Schroeder, will depart the Company effective December 15, 2023 to accept an external opportunity at Venture Medical, LLC, a national medical devices and wound care products distributor located in Missoula, Montana. The Company plans to retain external legal counsel on an interim basis to fulfill Mr. Schroeder’s former duties as General Counsel until a permanent successor can be identified, and will continue conducting its compliance procedures through a mix of existing internal and external resources.Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.066 loss in 3Q 2022)Third quarter 2023 results: US$0.037 loss per share (improved from US$0.066 loss in 3Q 2022). Revenue: US$24.7m (up 31% from 3Q 2022). Net loss: US$5.23m (loss narrowed 38% from 3Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 03Goodness Growth Holdings, Inc. to Report Q3, 2023 Results on Nov 14, 2023Goodness Growth Holdings, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023お知らせ • Sep 28Goodness Growth Holdings, Inc. Announces CFO ChangesGoodness Growth Holdings, Inc. announced that Chief Financial Officer, John Heller, will depart the Company effective September 30 to accept a new external opportunity. Interim Chief Executive Officer Josh Rosen will assume the additional role of Interim Chief Financial Officer.New Risk • Aug 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$7.9m). Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CA$25.4m market cap, or US$18.9m).Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.084 loss per share (vs US$0.048 loss in 2Q 2022)Second quarter 2023 results: US$0.084 loss per share (further deteriorated from US$0.048 loss in 2Q 2022). Revenue: US$20.2m (down 4.2% from 2Q 2022). Net loss: US$7.33m (loss widened 19% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.お知らせ • Aug 01Goodness Growth Holdings, Inc. to Report Q2, 2023 Results on Aug 14, 2023Goodness Growth Holdings, Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023New Risk • Jul 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-US$2.1m). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (CA$27.8m market cap, or US$21.1m).Reported Earnings • May 17First quarter 2023 earnings released: US$0.066 loss per share (vs US$0.11 loss in 1Q 2022)First quarter 2023 results: US$0.066 loss per share (improved from US$0.11 loss in 1Q 2022). Revenue: US$19.1m (up 22% from 1Q 2022). Net loss: US$8.41m (loss narrowed 42% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • May 10Goodness Growth Holdings, Inc. to Report Q1, 2023 Results on May 15, 2023Goodness Growth Holdings, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023お知らせ • Feb 15+ 1 more updateGoodness Growth Holdings, Inc. Announces Management ChangesGoodness Growth Holdings, Inc. announced that Company founder, Dr. Kyle Kingsley, will assume the role of Executive Chairman. Chief Administrative Officer Amber Shimpa has been promoted to the role of President of the Company.Price Target Changed • Jan 13Price target decreased to CA$0.85Down from CA$1.00, the current price target is provided by 1 analyst. New target price is 270% above last closing price of CA$0.23. The company posted a net loss per share of US$0.27 last year.お知らせ • Dec 10Goodness Growth Holdings, Inc. Announces Departure of Christian Gonzalez-Ocasio as Chief Operating OfficerGoodness Growth Holdings, Inc. announced the departure of Chief Operating Officer, Christian Gonzalez-Ocasio. The Company intends to engage Mr. Gonzalez as a consultant for an interim period to help ensure a smooth transition with the Company's leadership team. Mr. Gonzalez had been serving as Chief Operating Officer of the Company since November 2020. He previously served as Executive Vice President of Operations, supporting manufacturing and retail initiatives, beginning in October 2019. The Company does not plan to immediately seek a replacement for the Chief Operating Officer position. Responsibilities of the position will be filled by a mix of existing internal resources.お知らせ • Dec 06Goodness Growth Holdings, Inc Appoints Josh Rosen to the Role of Interim PresidentGoodness Growth Holdings, Inc. announced that it has appointed Josh Rosen to the role of Interim President, effective immediately. Mr. Rosen has been serving as a director of the Company since August 2021. While he will continue to serve on the Company's board of directors, his position as Interim President will significantly expand his roles and responsibilities. Mr. Rosen's new roles and responsibilities will focus on driving operational efficiencies and adult-use preparedness in the Company's various operating markets to better align resources to capitalize on the growing adoption of adult-use regulations and managing the Company's key capital and strategic relationships. Goodness Growth's C-Suite of executives will begin reporting directly to Mr. Rosen, effective immediately. Dr. Kyle Kingsley will continue in his role as Chairman and Chief Executive Officer, with primary responsibilities focused on collaborating with Mr. Rosen on strategy, government relations and the Company's ongoing commitment to effective medical cannabis products. Mr. Rosen and Dr. Kingsley will both report directly to the Company's Board of Directors. Mr. Rosen also serves as Managing Partner at Bengal Capital, and was formerly Chief Executive Officer and Chairman of 4Front Ventures. At 4Front, Josh helped lead the transformation of a pioneering industry consulting firm into an operations-focused, multi-state operator, notably including the acquisition of Cannex Capital. Prior to 4Front, Josh gained private equity experience managing the investment portfolio for a large family office and worked extensively in the public markets as an equity analyst, primarily at the global investment bank, Credit Suisse.お知らせ • Nov 11Goodness Growth Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022Goodness Growth Holdings, Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022お知らせ • Oct 15Goodness Growth Holdings, Inc., Annual General Meeting, Nov 18, 2022Goodness Growth Holdings, Inc., Annual General Meeting, Nov 18, 2022.業績と収益の成長予測CNSX:VREO - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,233N/A130167112/31/20271,1401282117212/31/2026778-9-727126/30/2026512-67-11826N/A3/31/2026350-82-2119N/A12/31/2025269-68-264N/A9/30/2025189-63-44-21N/A6/30/2025123-42-30-17N/A3/31/2025100-28-24-12N/A12/31/202499-28-22-10N/A9/30/202499-17-16-4N/A6/30/202498-17-80N/A3/31/202493-24-52N/A12/31/202388-26-7-1N/A9/30/202383-34-11-7N/A6/30/202377-37-15-10N/A3/31/202378-36-19-15N/A12/31/202275-42-23-18N/A9/30/202269-42-28-20N/A6/30/202264-41-34-23N/A3/31/202257-41-47-32N/A12/31/202154-34-49-31N/A9/30/202153-23-42-23N/A6/30/202152-13-39-21N/A3/31/202150-22-26-13N/A12/31/202049-23-19-11N/A9/30/202048-63-27-22N/A6/30/202042-78-30-25N/A3/31/202036-62N/A-28N/A12/31/201930-57N/A-27N/A9/30/201925-17N/A-19N/A6/30/201922-4N/A-17N/A3/31/201921-4N/A-10N/A12/31/201818-3N/A-9N/A9/30/201816-2N/A-6N/A12/31/2017110N/A-1N/A12/31/201646N/A-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VREOは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.1% ) よりも高い成長率であると考えられます。収益対市場: VREO今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: VREO今後 3 年以内に収益を上げることが予想されます。収益対市場: VREOの収益 ( 24% ) Canadian市場 ( 4.3% ) よりも速いペースで成長すると予測されています。高い収益成長: VREOの収益 ( 24% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VREOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/23 18:33終値2026/08/21 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vireo Growth Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Matt BottomleyCanaccord GenuityThomas KerrZacks Small-Cap ResearchSung-Chul KimZacks Small-Cap Research1 その他のアナリストを表示
Price Target Changed • Jan 13Price target decreased to CA$0.85Down from CA$1.00, the current price target is provided by 1 analyst. New target price is 270% above last closing price of CA$0.23. The company posted a net loss per share of US$0.27 last year.
お知らせ • Aug 22Vireo Growth Inc. (CNSX:VREO) completed the acquisition of C21 Investments Inc. (CNSX:CXXI).Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $35.7 million on June 14, 2026. Vireo agreed to acquire all of the issued and outstanding common shares (collectively, the “C21 Shares”) after exchange of all subordinate voting shares of C21 into C21 Shares. Under the Arrangement, each issued and outstanding subordinate voting share of C21 (other than any C21 Share held by a dissenting shareholder) will be exchanged for 0.000001 common shares of C21. Following such exchange, each C21 common share outstanding will be transferred to Vireo in exchange for 0.023052 subordinate voting shares of Vireo. Subject to the satisfaction of all conditions to closing, upon completion of the Transaction, it is expected that the C21 Shares will be delisted from the Canadian Securities Exchange and the OTCQX Market and that C21 will apply to cease to be a reporting issuer under applicable Canadian and U.S. securities laws. In case of termination of transaction, seller will pay a termination fee of $3 million. The transaction is subject to subject to court approval, approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board and approval of offer by target shareholders. The Board of Directors of C21 Investments Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board. The special meeting for the shareholders of C21 Investments will be held to approve the transaction on August 7, 2026. The transaction is expected to close in the third quarter of 2026. On August 7, 2026, shareholders of C21 approved the transaction. C21 plans to apply for a final order of the Supreme Court of British Columbia for approval of the Arrangement on August 13, 2026. Assuming the satisfaction or waiver of other customary closing conditions and subject to the receipt of all relevant regulatory and court approvals, the transaction is expected to close on or about August 21, 2026. Needham & Company, LLC is acting as financial advisor to the C21 Board and provided the Independent Fairness Opinion to the C21 Board. Mikhail Ilinets and Amy Laverdure of Koffman Kalef LLP and Dorsey & Whitney LLP acted as legal advisor for C21 Investments Inc. Derek Bell, Russel Drew and Jamie Mandell of DLA Piper LLP acted as legal advisor for Vireo Growth Inc. Matthew Block and Craig Alcorn of Eversheds Sutherland LLP acted as legal advisor for Vireo Growth Inc. Computershare Investor Services Inc. acted as transfer agent for C21 Investments Inc. Davidson & Company LLP acted as accountant for C21 Investments Inc. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of C21 Investments Inc. (CNSX:CXXI) on August 21, 2026.
New Risk • Aug 20New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$118m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$118m free cash flow). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding).
New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Minor Risk Less than 1 year of cash runway based on current free cash flow (-US$118m).
Reported Earnings • Aug 11Second quarter 2026 earnings released: US$0.002 loss per share (vs US$0.80 loss in 2Q 2025)Second quarter 2026 results: US$0.002 loss per share (improved from US$0.80 loss in 2Q 2025). Revenue: US$209.3m (up 336% from 2Q 2025). Net loss: US$100.0k (loss narrowed 99% from 2Q 2025). Profit margin: 0% (up from net loss in 2Q 2025). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 42% per year whereas the company’s share price has increased by 45% per year.
お知らせ • Aug 08Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Certain retail assets and properties of PharmaCann Inc.Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for approximately $49 million on December 16, 2025. Total consideration is payable in subordinate voting shares of the Vireo Growth, as well as the assumption of certain liabilities. On March 22, 2026, a Management Services Agreement (MSA) became effective, allowing an affiliate of Vireo to manage the assets in the interim. On the same date, 90,740,741 subordinate voting shares were delivered into escrow pending the close of the acquisition. The transaction is expected to close in the second fiscal quarter of 2026, subject to regulatory approval. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Certain retail assets and properties of PharmaCann Inc. on August 7, 2026.Total consideration for the acquired assets was approximately $49.0 million, consisting of the issuance of Vireo subordinate voting shares and the assumption of certain liabilities. The final share consideration reflects customary closing adjustments, including inventory levels, trade payables and other items as provided for in the Asset Purchase Agreement. The acquired business includes 17 dispensaries.
お知らせ • Aug 04Vireo Growth Inc. to Report Q2, 2026 Results on Aug 11, 2026Vireo Growth Inc. announced that they will report Q2, 2026 results Pre-Market on Aug 11, 2026
お知らせ • Aug 01Vireo Growth Inc. (CNSX:VREO) entered into a definitive securities purchase agreement to acquire FARMACEUTICALRX LLC.Vireo Growth Inc. (CNSX:VREO) entered into a definitive securities purchase agreement to acquire FARMACEUTICALRX LLC on July 31, 2026. In a separate related transactions, Vireo Growth Inc. entered into a definitive securities purchase agreements to acquire FarmaceuticalRx 2 LLC, CAOH LLC, and Canoe Hill Ohio, LLC on July 31, 2026. Collectively, the acquired businesses include eight dispensaries, a cultivation and processing facility, and related owned and leased real estate, establishing a vertically integrated operating platform in Ohio. Subject to customary adjustments for cash, debt, pre-closing taxes and transaction expenses, the aggregate purchase price across all four acquisitions is expected to be approximately $208 million, which will be satisfied by issuing approximately 11 million subordinate voting shares of Vireo. The subordinate voting shares will be issued in three tranches, with 50% of the consideration issued at closing, 25% approximately 90 days following closing, and the remaining 25% approximately 180 days following closing. The deferred consideration in each Ohio Transaction is subject to the continued performance of the acquired businesses and a forfeiture mechanism entitling Vireo to claw back up to 25% of the subordinate voting shares issued to the various Sellers if specified performance thresholds and other conditions specified in the purchase agreements are not met during the applicable measurement periods. Following the completion of the Ohio Transactions, the Ohio Entities and their subsidiaries will join Vireo’s growing cannabis segment. The transaction is subject to the receipt of all required regulatory approvals and the satisfaction of certain other closing conditions customary in transactions of this nature. Closing is expected to occur in Q4 2026, subject to the satisfaction of all closing conditions.
お知らせ • Jul 28Vireo Growth Inc. (CNSX:VREO) entered into a definitive merger agreement to acquire Planet 13 Holdings Inc. (CNSX:PLTH) for $51.9 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive merger agreement to acquire Planet 13 Holdings Inc. (CNSX:PLTH) for $51.9 million on July 26, 2026. Under the terms of the agreement, each issued and outstanding share of common stock of Planet 13 will be converted into the right to receive 0.015 of a Vireo subordinate voting share. The price represents a 16.6% premium over Planet 13’s 20-day volume weighted average price per share as of July 24, 2026, the last trading day before the execution of the Merger Agreement. In case of termination of transaction, Planet 13 Holdings will pay a termination fee of $1.80 million. The transaction is subject to closing conditions, including obtaining Planet 13 stockholder approval, the effectiveness of a registration statement on Form S-4 to be filed with the U.S. Securities and Exchange Commission, approval of the listing of the Vireo shares issuable in the Transaction by the Canadian Securities Exchange, and applicable cannabis regulatory approvals. The Board of Directors of Planet 13 Holdings Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board of both companies. Upon completion of the transaction, it is expected that the Planet 13 shares of common stock will be delisted from the Canadian Securities Exchange and withdrawn from the OTCQX Market and that Planet 13 will apply to cease to be a reporting issuer under applicable United States and Canadian securities laws. ATB Cormark Capital Markets acted as financial advisor and fairness opinion provider to the Special Committee. Eversheds Sutherland (US) LLP and DLA Piper (Canada) LLP acted as legal advisors to Vireo. Cozen O’Connor is serving as legal advisor to Planet 13. Foley Hoag LLP is serving as legal advisor to the Special Committee
お知らせ • Jul 18Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC acquired FarmX, LLC.Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC entered into a Securities Purchase Agreement to acquire FarmX, LLC for $20 million on July 2, 2026. The total consideration consists of $8 million in cash payable at closing and $12 million payable through the issuance of approximately 645,161 subordinate voting shares of Vireo. The stock consideration is scheduled to be issued two years following the closing date. Post-transaction, the acquired permit will allow Vive Penn, LLC to operate up to six retail medical dispensaries in Pennsylvania. The transaction is subject to approval by regulatory board / committee and customary closing conditions. The transaction is expected to close two business days following the date the parties satisfy all conditions precedent to the agreement. Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC completed the acquisition of FarmX, LLC on July 17, 2026.
お知らせ • Jun 17Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million on June 15, 2026. The consideration consists of 2.72 million common equity of Vireo Growth Inc. at a ratio of 0.023052 per common equity of C21 Investments Inc. As part of consideration, an undisclosed value is paid towards common equity of C21 Investments Inc. In case of termination of transaction, seller will pay a termination fee of $3 million. The transaction is subject to subject to court approval, approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board and approval of offer by target shareholders. The Board of Directors of C21 Investments Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board. The transaction is expected to close in the third quarter of 2026. Needham & Company, LLC acted as fairness opinion provider and Koffman Kalef LLP, Dorsey & Whitney LLP and DLA Piper LLP acted as legal advisors for C21 Investments Inc. Eversheds Sutherland LLP acted as legal advisor for Vireo Growth Inc.
Buy Or Sell Opportunity • Jun 04Now 232% overvalued after recent price riseOver the last 90 days, the stock has risen 2,800% to CA$17.40. The fair value is estimated to be CA$5.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last 3 years. Earnings per share has grown by 40%.
お知らせ • May 26Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million.Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million on May 25, 2026. The consideration consists of convertible debt of Vireo Growth Inc. having a value of $10.26 million to be issued for common equity of Bridgewell Agribusiness LLC. The aggregate consideration for the Bridgewell Transaction is based on a base purchase price of US$40 million, subject to adjustments for, among other things, approximately US$30 million of assumed indebtedness of Bridgewell that will remain outstanding following closing and the assumption of certain other transaction expenses. After giving effect to such adjustments, the estimated closing purchase price is expected to be approximately US$10.26 million In exchange for the issued and outstanding membership interests of Bridgewell, Vireo will issue an unsecured, subordinated convertible note to the Seller (the “Convertible Note”) in the aggregate principal amount equal to the closing purchase price, which will automatically convert on or after the second anniversary of closing into an estimated 16,552,150 subordinate voting shares of Vireo (the “Consideration Shares”) at a deemed price of US$0.62 per Consideration Share (which final price will be subject to the policies of the Canadian Securities Exchange and based on the volume weighted average trading price of the Company’s subordinate voting shares for 20 consecutive trading days ending two trading days prior to the closing date). The aggregate principal amount of the Convertible Note and number of Consideration Shares issuable thereunder are subject to certain post-closing purchase price and other adjustments. The transaction is subject to approval by regulatory board / committee and definitive agreement. The Bridgewell Transaction could close any time following five (5) business days.
Reported Earnings • May 13First quarter 2026 earnings released: US$0.019 loss per share (vs US$0.018 loss in 1Q 2025)First quarter 2026 results: US$0.019 loss per share (further deteriorated from US$0.018 loss in 1Q 2025). Revenue: US$106.2m (up 333% from 1Q 2025). Net loss: US$20.3m (loss widened 212% from 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.
お知らせ • May 07Vireo Growth Inc. to Report Q1, 2026 Results on May 12, 2026Vireo Growth Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026
お知らせ • May 02Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million on April 30, 2026. As part of the acquisition, Vireo Growth Inc. will acquire all of the issued and outstanding common shares of FLUENT Corp. As part of consideration, each shareholder of FLUENT Corp will receive 0.0705359 of a subordinate voting share of Vireo Growth Inc in exchange for each FLUENT Corp Share held. Following the completion of the Transaction, FLUENT will join the Vireo ecosystem and gain exposure to a larger and well capitalized multi-state operator currently operating in 10 states across the U.S. In connection with the Transaction, Vireo has entered into voting support agreements with certain directors, officers and key shareholders of FLUENT, with such holders representing approximately 38.3% of the issued and outstanding FLUENT Shares, pursuant to which they have agreed to, among other things, vote their FLUENT Shares in favor of the Transaction. Chris Hagedorn has resigned from the FLUENT Board. The vacancy will not be filled at this time. Upon completion, it is expected that the FLUENT Shares will be delisted from the Canadian Securities Exchange (“CSE”) and the OTCQB Venture Market and that FLUENT will apply to cease to be a reporting issuer under applicable Canadian securities laws. In case of termination of transaction, FLUENT Corp. will pay a termination fee of $2 million to Vireo Growth Inc. The transaction is subject to court approvals, as well as the receipt of all required regulatory approvals, the completion of the Equitization, and the satisfaction of certain other closing conditions customary in transactions of this nature, approval by the shareholders of FLUENT Corp and other third-party approvals. The Board of Directors of FLUENT Corp. formed a special committee for the transaction. The Special Committee and the FLUENT Board have unanimously determined that the Transaction is in the best interests of FLUENT and is fair to the FLUENT Shareholders and the FLUENT Board recommends that the FLUENT Shareholders vote in favor of the Transaction. The transaction is expected to close in the fourth quarter of 2026. ATB Cormark Capital Markets acted as fairness opinion provider to the Special Committee and board of directors of FLUENT Corp. ATB Cormark Capital Markets acted as financial advisor to the Special Committee of FLUENT Corp. Cassels Brock & Blackwell LLP acted as legal advisor to FLUENT Corp. Goodwin Procter LLP acted as legal advisor to FLUENT Corp. DLA Piper (Canada) LLP acted as legal advisor to Vireo Growth Inc. Eversheds Sutherland (US) LLP acted as legal advisor to Vireo Growth Inc. Shenker Russo & Clark LLP acted as legal advisor to Vireo Growth Inc. Foley & Lardner LLP acted as legal advisor to Vireo Growth Inc.
お知らせ • Apr 17Vireo Growth Inc. announced that it has received $50.612571 million in fundingOn April 16, 2026. Vireo Growth Inc. announced that it has closed the transaction.
お知らせ • Apr 09Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million.Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. for approximately $120 million on January 15, 2026. As part of consideration Vireo Growth Inc. issued 206 million ordinary shares, a warrant to purchase 80 million at an exercise price of $0.85 per Share, exercisable for a period of five years from the date of issuance. Additional Vireo Growth Inc. acquire The Hawthorne Gardening Company $35 million of cash, approximately $50 million of net working capital, and would be provided approximately $20 million of inventory. Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors upon completion of the transition upon completion of the transaction and shareholder approval. The transaction is subjected to regulatory approvals and the finalization of a definitive agreement. If applicable, the approval of the Canadian Securities Exchange. The expected to be completed during the second quarter of 2026. Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million on April 8, 2026. Under the terms of the transaction, Vireo Growth Inc. acquired $35 million of cash held by Hawthorne, and issued 213 million of its subordinate voting shares and a warrant to purchase 80 million at an exercise price of $0.85 per Share.
お知らせ • Apr 01Vireo Growth Inc. Announces Cory Azzalino to Step into the CEO Role of Vireo’s California BusinessVireo Growth Inc. announced Cory Azzalino will step into the CEO role of Vireo’s California business – Cory and his team bring operational acumen and emphasis on retail excellence which strengthens Vireo’s platform.
Reported Earnings • Mar 18Full year 2025 earnings released: US$0.093 loss per share (vs US$0.15 loss in FY 2024)Full year 2025 results: US$0.093 loss per share. Revenue: US$268.8m (up 170% from FY 2024). Net loss: US$68.1m (loss widened 143% from FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Mar 17Vireo Growth Inc., Annual General Meeting, May 29, 2026Vireo Growth Inc., Annual General Meeting, May 29, 2026.
お知らせ • Mar 10Vireo Growth Inc. to Report Q4, 2025 Results on Mar 17, 2026Vireo Growth Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 17, 2026
お知らせ • Jan 28Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding Memorandum of Understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc.Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. on January 28, 2026. Upon completion, Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors.
Recent Insider Transactions Derivative • Jan 02President exercised options and sold CA$104k worth of stockOn the 29th of December, Amber Shimpa exercised options to acquire 127k shares at no cost and sold these for an average price of CA$0.82 per share. This trade did not impact their existing holding. Since March 2025, Amber's direct individual holding has increased from 875.63k shares to 1.97m. This was the only transaction from an insider over the last 12 months.
分析記事 • Dec 30Vireo Growth Inc.'s (CSE:VREO) 38% Jump Shows Its Popularity With InvestorsVireo Growth Inc. ( CSE:VREO ) shareholders are no doubt pleased to see that the share price has bounced 38% in the...
お知らせ • Dec 23Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million.Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million on December 22, 2025. The consideration is payable through the issuance of approximately 84 million subordinate voting shares of the Vireo at closing. Total consideration payable in the transaction will be subject to adjustment based on closing levels of cash, indebtedness, tax obligations and working capital adjustments, as well as the occurrence of certain other events by the closing date. Eaze may be entitled to earn-out consideration as of December 31, 2026. Eaze will become a wholly-owned subsidiary of Vireo. The expected completion of the transaction is January 1, 2026 to June 30, 2026.
お知らせ • Dec 18Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million.Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million on December 16, 2025. Total consideration is payable in subordinate voting shares of the Vireo Growth, as well as the assumption of certain liabilities. The transaction is subject to satisfaction of closing conditions and state and local regulatory approvals. The transaction is expected to close during the first half of calendar year 2026.
分析記事 • Nov 15With A 35% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay ForThe Vireo Growth Inc. ( CSE:VREO ) share price has fared very poorly over the last month, falling by a substantial 35...
New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 1.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 1.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (362% increase in shares outstanding).
Reported Earnings • Nov 14Third quarter 2025 earnings released: US$0.042 loss per share (vs US$0.024 loss in 3Q 2024)Third quarter 2025 results: US$0.042 loss per share (further deteriorated from US$0.024 loss in 3Q 2024). Revenue: US$91.7m (up 264% from 3Q 2024). Net loss: US$26.3m (loss widened 434% from 3Q 2024). Revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 31Vireo Growth Inc. to Report Q3, 2025 Results on Nov 12, 2025Vireo Growth Inc. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025
お知らせ • Oct 29Vireo Growth Inc. and Verano Holdings Corp. Reaches Comprehensive Settlement Dismissing All Outstanding Litigation MattersVireo Growth Inc. and Verano Holdings Corp. on October 29, 2025 announced that they have reached a comprehensive settlement dismissing all outstanding litigation matters between the two Companies that are pending before the Supreme Court of British Columbia, Canada. The terms of the Settlement Agreement were approved by the respective Boards of Directors of both Companies. The value of the settlement to Vireo is approximately USD 10 million consisting of the acquisition of certain real estate assets and USD 1 million in cash. The resolution marks the conclusion of a complex legal chapter and reflects a commitment by both Companies to move forward in a constructive manner. Both Companies reiterated their dedication to delivering long-term value to their shareholders and quality products and services to their customers.
お知らせ • Oct 24Vireo Growth Inc. announced that it has received $61.996221 million in fundingOn October 23, 2025, Vireo Growth Inc closed the transaction. The transaction included participation from 22 investors.
お知らせ • Sep 16Vireo Growth Inc. Announces Launch of Adult-Use Cannabis Sales in MinnesotaVireo Growth Inc. announced that on September 16, 2025, it recorded its first sale of adult use cannabis in Minnesota at its historic downtown Minneapolis Green Goods® dispensary. The Company is now dispensing a full suite of both medical and adult-use cannabis products at all eight of its Green Goods™ dispensaries located throughout the State of Minnesota. Vireo has been operating in Minnesota’s medical cannabis market since 2014, serving tens of thousands of patients with safe, reliable products. The Company is committed to expanding access, improving product quality, and supporting the state’s transition to a sustainable, locally driven adult-use market. As one of the state’s operational licensed adult-use cannabis cultivators and retailers, and a population of 5.7 million people, the launch of Minnesota’s adult-use cannabis market is expected to serve as a strong organic revenue growth catalyst for Vireo for the foreseeable future. Green Goods® offers a full suite of medical and adult-use cannabis products and form factors including flower, pre-rolls, edibles, and beverages, and currently operates eight retail dispensaries in Minnesota. Green Goods® dispensaries are located in Minneapolis, Blaine, Bloomington, Burnsville, Duluth, Moorhead, Rochester, and Woodbury. For more information about Green Goods or to shop its product menu, please visit www.visitgreengoods.com.
分析記事 • Sep 11With A 33% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay ForVireo Growth Inc. ( CSE:VREO ) shares have retraced a considerable 33% in the last month, reversing a fair amount of...
Reported Earnings • Aug 14Second quarter 2025 earnings released: US$0.027 loss per share (vs US$0.005 loss in 2Q 2024)Second quarter 2025 results: US$0.027 loss per share (further deteriorated from US$0.005 loss in 2Q 2024). Revenue: US$48.1m (up 91% from 2Q 2024). Net loss: US$14.9m (loss widened US$14.3m from 2Q 2024). Revenue is forecast to grow 78% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Aug 05Vireo Growth Inc. to Report Q2, 2025 Results on Aug 13, 2025Vireo Growth Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 13, 2025
お知らせ • Jul 10Vireo Growth Inc. announced that it has received $10 million in funding from Chicago Atlantic Opportunity Finance, LLCVireo Growth Inc announced that it has completed a private placement and issued $10,000,000 principal amount of convertible Notes on July 9, 2025. The Notes are convertible into an aggregate of 16,000,000 Shares upon exercise. The new convertible note was issued in reliance upon exemptions from the registration requirements of the U.S. Securities Act of 1933, as amended and applicable Canadian and U.S state Securities laws. The transaction included participation from Chicago Atlantic Opportunity Finance, LLC.
お知らせ • Jun 10Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million.Vireo Growth Inc. (CNSX:VREO) has signed definitive agreement to acquire Deep Roots Harvest, Inc. on December 18, 2024. Total consideration is approximately $397 million of all-stock transactions. In Related transactions Vireo has signed definitive agreements to acquire Proper Brands in Missouri and WholesomeCo Cannabis in Utah, while also signing a binding MOU to acquire The Flowery in Florida. Vireo estimates proforma revenue and EBITDA of the combined company of approximately $394 million and $94 million, respectively, for calendar year 2024. Upon closing of the Merger Transactions, Vireo estimates the combined company will be well-positioned for further growth with a favorable balance sheet consisting of approximately $99 million of cash and $78 million of net debt with an EBITDA leverage ratio of approximately 0.8x. The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. The Deep Roots Merger Agreement also contains customary indemnification obligations of Vireo and Deep Roots, other obligations of the parties and termination provisions, under which, subject to certain conditions and in certain instances of termination, would require Vireo or Deep Roots to pay a termination fee equal to $6.37624 million. These acquisition targets may qualify for earnout payments on December 31, 2026, based on 4x EBITDA growth compared to Reference EBITDA, adjusted for incremental debt, and paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. Reference EBITDA for Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are $31.0 million, $31.0 million, and $16.0 million, respectively. John Mazarakis, co-founder at Chicago Atlantic, has been appointed to the role of Chief Executive Officer and Co-Executive Chairman, effective immediately. Tyson Macdonald, former partner at TrueRise Capital, has been appointed to the role of Chief Financial Officer, effective immediately. Amber Shimpa will continue to serve as President of the Company and as Chief Executive Officer of Minnesota, Maryland, and New York. Implementation of the Merger Transactions are subject to the approval of holders of a majority of Vireo's voting shares and regulatory approvals. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and each of the target acquisition companies. Vireo anticipates that closing of all of the Merger Transactions to take at least six months pending shareholder and regulatory approvals. Vireo expects that each transaction will be accretive to the broader portfolio. Moelis & Company LLC acted as fairness opinion provider for Boards of Directors of Vireo Growth Inc. Moelis & Company LLC acted as financial advisor for Vireo Growth Inc. Dorsey & Whitney LLP acted as legal advisor for Vireo Growth Inc. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million on June 9, 2025. Total consideration for the transaction is paid in the form of 255.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52. The purchase price of the Deep Roots transaction represents a multiple of 4.175x 2024 “Closing EBITDA” of $30 million.
お知らせ • Jun 06Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands on December 18, 2024. Under the terms of the transaction, the transaction is expected to be effected by way of an all-stock transaction, and The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. Reference EBITDA for Proper Brands is $31.0 million. Vireo will include in the stock merger consideration calculation an amount equal to $2,139,200 for the stockholders of Proper Brands for all of the outstanding equity interests in Arches IP, Inc. owned by Proper Brands with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The seller of Proper Brand has agreed to voluntary share lock-up after 33 months of consummation. In separate transactions, Vireo will also acquire Deep Roots Harvest, WholesomeCo Cannabis, and The Flowery. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board, subject to shareholder approval and lock-up agreement, and a clawback provision if they perform below the respective Reference EBITDA measured as the higher of trailing twelve-months or nine-months annualized EBITDA as of December 31, 2026, adjusted for any intercompany funding. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and Proper Brands. In certain instances of termination, Vireo or Proper Brands is required to pay a termination fee equal to $4,631,012. Moelis & Company LLC acted as financial advisor and Fairness Opinion Provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million on June 5, 2025. Total consideration for the transactions was $102 million, paid in the form of 196.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52.
お知らせ • May 13Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis.Vireo Growth Inc. (CNSX:VREO) signed an agreement to acquire WholesomeCo Cannabis on December 18, 2024. Vireo has signed three definitive documents and one binding Memorandum of Understanding to acquire four single-state operators (Proper Brands, Deep Roots Harvest, and Bill’s Nursery, Inc, WholesomeCo Cannabis) for total consideration of approximately $397 million in a series of all-stock transactions and may qualify for earnout payments on December 31, 2026. Vireo will include in the stock merger consideration calculation an amount equal to $11,860,800 for the stockholders of WholesomeCo Cannabis for all of the outstanding equity interests in Arches IP, Inc. owned by WholesomeCo Cannabis with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The transaction is subject to certain shareholder and regulatory approvals, and clawback provision. In certain instances of termination, Vireo or WholesomeCo Cannabis is required to pay a termination fee equal to $3,394,217. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and WholesomeCo Cannabis. As of March 9, 2025, Vireo Growth Inc. has obtained required regulatory approvals and is working toward satisfying all other customary closing conditions, which it expects to meet during the second quarter of 2025. Moelis & Company LLC acted as financial advisor and fairness opinion provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing. Adam Hull of Polsinelli PC acted as legal advisor to WholesomeCo. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis for $69.8 million on May 12, 2025. $69.8 million paid in the form of 134.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52.
Reported Earnings • May 10First quarter 2025 earnings released: US$0.018 loss per share (vs US$0.047 loss in 1Q 2024)First quarter 2025 results: US$0.018 loss per share (improved from US$0.047 loss in 1Q 2024). Revenue: US$24.5m (up 1.9% from 1Q 2024). Net loss: US$6.51m (loss narrowed 3.0% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • Apr 29Vireo Growth Inc. to Report Q1, 2025 Results on May 09, 2025Vireo Growth Inc. announced that they will report Q1, 2025 results Pre-Market on May 09, 2025
お知らせ • Apr 09Vireo Growth Inc., Annual General Meeting, Jun 20, 2025Vireo Growth Inc., Annual General Meeting, Jun 20, 2025.
分析記事 • Apr 04Revenues Not Telling The Story For Vireo Growth Inc. (CSE:VREO) After Shares Rise 26%Vireo Growth Inc. ( CSE:VREO ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...
分析記事 • Mar 31Is Vireo Growth (CSE:VREO) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Reported Earnings • Mar 04Full year 2024 earnings released: US$0.15 loss per share (vs US$0.19 loss in FY 2023)Full year 2024 results: US$0.15 loss per share. Revenue: US$99.4m (up 13% from FY 2023). Net loss: US$28.0m (loss widened 9.6% from FY 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Feb 20Vireo Growth Inc. to Report Q4, 2024 Results on Mar 04, 2025Vireo Growth Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025
お知らせ • Jan 01Vireo Growth Inc. announced that it has received $80.960546 million in fundingOn December 30, 2024, Vireo Growth Inc., closed the transaction. The company issued 129,536,874 subordinate voting shares at a price of $0.625 per share for the gross proceeds of $80,960,546.25 in the transaction. The transaction has been oversubscribed.
お知らせ • Dec 19+ 4 more updatesVireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands on December 18, 2024. Under the terms of the transaction, the transaction is expected to be effected by way of an all-stock transaction, and The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. These acquisition targets may qualify for earnout payments on December 31, 2026, based on 4x EBITDA growth compared to Reference EBITDA, adjusted for incremental debt, and paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. Reference EBITDA for Proper Brands is$31.0 million. Total payment for Arches includes $14 million in upfront consideration to WholesomeCo and Proper Brands with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The seller of Bill's Nursery has agreed to voluntary share lock-up after 33 months of consummation. In separate transactions, Vireo will also acquire Deep Roots Harvest, WholesomeCo Cannabis, and The Flowery. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board, subject to shareholder approval and lock-up agreement, and a clawback provision if they perform below the respective Reference EBITDA measured as the higher of trailing twelve-months or nine-months annualized EBITDA as of December 31, 2026, adjusted for any intercompany funding. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and Bill's Nursery. Moelis & Company LLC acted as financial advisor and Fairness Opinion Provider, and Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing.
分析記事 • Nov 27Risks Still Elevated At These Prices As Vireo Growth Inc. (CSE:VREO) Shares Dive 26%Vireo Growth Inc. ( CSE:VREO ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
Reported Earnings • Nov 15Third quarter 2024 earnings released: US$0.024 loss per share (vs US$0.037 loss in 3Q 2023)Third quarter 2024 results: US$0.024 loss per share (improved from US$0.037 loss in 3Q 2023). Revenue: US$25.2m (up 2.0% from 3Q 2023). Net loss: US$4.93m (loss narrowed 5.8% from 3Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
お知らせ • Nov 05Vireo Growth Inc. announced that it expects to receive $10 million in fundingVireo Growth Inc. announced that it has secured a new convertible debt facility which provides a financing commitment of up to $10,000,000 in aggregate principal amount of convertible notes on November 4, 2024. This facility is being funded by the Company’s senior secured lender and its affiliates under the Company’s existing credit agreement. The convertible facility has a term of three years, with a cash interest rate of 12.0 percent, and such interest shall be paid to Lender in cash on the last business day of each calendar month. The Convertible Notes shall be convertible at any time into Subordinate Voting Shares of the Company, at the option of Lender, in whole but not in part, in a single transaction, at a conversion price equal to $0.625.
お知らせ • Oct 30Vireo Growth Inc. to Report Q3, 2024 Results on Nov 13, 2024Vireo Growth Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024
New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: CA$110.5m (US$80.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Market cap is less than US$100m (CA$110.5m market cap, or US$80.3m).
分析記事 • Oct 12Vireo Growth Inc.'s (CSE:VREO) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatioVireo Growth Inc. ( CSE:VREO ) shares have had a horrible month, losing 29% after a relatively good period beforehand...
お知らせ • Oct 11+ 1 more updateVireo Growth Inc. Announces CFO ChangesVireo Growth Inc. announced several leadership updates. Josh Rosen has resigned from the Company's interim Chief Financial Officer, effective immediately, to focus on his other business ventures. Mr. Rosen was first elected to the Board in August 2021, and appointed to executive leadership roles in November 2022, including, most recently, the roles of Chief Executive Officer and interim Chief Financial Officer. The Company has engaged Mr. Rosen going forward with a consulting agreement. Joe Duxbury has been appointed as Interim Chief Financial Officer while the Company searches for a permanent replacement. Mr. Duxbury has been with the Company since 2019 in financial and accounting roles of increasing responsibility, and most recently was serving as Vice President of Finance leading external reporting and investor relations.
お知らせ • Oct 10Vireo Growth Inc. Announces Resignation of Josh Rosen as DirectorVireo Growth Inc. announced several leadership updates. Josh Rosen has resigned from the Company's Board of Directors, effective immediately, to focus on his other business ventures. Mr. Rosen was first elected to the Board in August 2021, and appointed to executive leadership roles in November 2022, including, most recently, the roles of Chief Executive Officer and interim Chief Financial Officer. The Company has engaged Mr. Rosen going forward with a consulting agreement.
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. CEO, Interim CFO & Director Josh Rosen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Aug 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).
お知らせ • Aug 20Vireo Growth Inc. announced that it has received $5.3875 million in fundingOn August 20, 2024, Vireo Growth Inc. closed the transaction. The transaction included participation from 14 investors.
分析記事 • Aug 10Vireo Growth Inc. (CSE:VREO) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedVireo Growth Inc. ( CSE:VREO ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...
Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.057 loss in 2Q 2023)Second quarter 2024 results: US$0.005 loss per share (improved from US$0.057 loss in 2Q 2023). Revenue: US$25.1m (up 24% from 2Q 2023). Net loss: US$668.4k (loss narrowed 91% from 2Q 2023). Revenue is expected to decline by 1.4% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Canada are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
お知らせ • Jul 23Vireo Growth Inc. to Report Q2, 2024 Results on Aug 06, 2024Vireo Growth Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024
分析記事 • Jun 01Market Might Still Lack Some Conviction On Goodness Growth Holdings, Inc. (CSE:GDNS) Even After 30% Share Price BoostGoodness Growth Holdings, Inc. ( CSE:GDNS ) shares have continued their recent momentum with a 30% gain in the last...
お知らせ • May 31Goodness Growth Holdings, Inc. announced that it expects to receive $0.7 million in fundingGoodness Growth Holdings, Inc. announced a non-brokered private placement of its subordinate voting shares for the gross proceeds of $700,000 on May 30, 2024. The company expects that this transaction will be completed within the next five business days. All of the subordinate voting shares issued in connection with this private placement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
Reported Earnings • May 08First quarter 2024 earnings released: US$0.047 loss per share (vs US$0.066 loss in 1Q 2023)First quarter 2024 results: US$0.047 loss per share (improved from US$0.066 loss in 1Q 2023). Revenue: US$24.1m (up 26% from 1Q 2023). Net loss: US$6.71m (loss narrowed 20% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
お知らせ • May 03+ 1 more updateGoodness Growth Holdings, Inc. Appoints Josh Rosen as Chief Executive OfficerGoodness Growth Holdings, Inc. announced several leadership and corporate updates related to the day-to-day management of its business. Josh Rosen, who has served as Interim CEO since February of 2023, has been appointed as Chief Executive Officer, effective immediately. Josh Rosen’s leadership over the course of the past 14 months has been instrumental in securing a path forward for Company as a standalone enterprise. The company have been immensely impressed with Josh’s stewardship of the organization through the exceptionally challenging circumstances that were created by Verano’s wrongful termination of merger agreement. During his tenure as Interim CEO, he has significantly improved fundamental operating and financial performance, and has represented the Company admirably in his interactions with both internal and external stakeholders.
お知らせ • May 01Goodness Growth Holdings, Inc. to Report Q1, 2024 Results on May 07, 2024Goodness Growth Holdings, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024
お知らせ • Apr 13Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024.
分析記事 • Apr 06Goodness Growth Holdings, Inc. (CSE:GDNS) Stock Rockets 30% But Many Are Still Ignoring The CompanyDespite an already strong run, Goodness Growth Holdings, Inc. ( CSE:GDNS ) shares have been powering on, with a gain of...
お知らせ • Apr 03Goodness Growth Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023Goodness Growth Holdings, Inc. reported impairment charges for the fourth quarter ended December 31, 2023. For the period, the company reported loss on impairment of long-lived assets of USD 411,629 compared to USD 1,119,583 last year same period.
Reported Earnings • Apr 02Full year 2023 earnings released: US$0.19 loss per share (vs US$0.33 loss in FY 2022)Full year 2023 results: US$0.19 loss per share (improved from US$0.33 loss in FY 2022). Revenue: US$88.1m (up 18% from FY 2022). Net loss: US$25.5m (loss narrowed 40% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 15Goodness Growth Holdings, Inc. to Report Q4, 2023 Results on Mar 28, 2024Goodness Growth Holdings, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 28, 2024
分析記事 • Feb 01Investors Still Aren't Entirely Convinced By Goodness Growth Holdings, Inc.'s (CSE:GDNS) Revenues Despite 59% Price JumpGoodness Growth Holdings, Inc. ( CSE:GDNS ) shares have continued their recent momentum with a 59% gain in the last...
お知らせ • Dec 15Goodness Growth Holdings, Inc. Announces Departure of Michael Schroeder as General Counsel & Chief Compliance Officer Effective December 15, 2023Goodness Growth Holdings, Inc. announced that the Company’s General Counsel and Chief Compliance Officer, Michael Schroeder, will depart the Company effective December 15, 2023 to accept an external opportunity at Venture Medical, LLC, a national medical devices and wound care products distributor located in Missoula, Montana. The Company plans to retain external legal counsel on an interim basis to fulfill Mr. Schroeder’s former duties as General Counsel until a permanent successor can be identified, and will continue conducting its compliance procedures through a mix of existing internal and external resources.
Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.066 loss in 3Q 2022)Third quarter 2023 results: US$0.037 loss per share (improved from US$0.066 loss in 3Q 2022). Revenue: US$24.7m (up 31% from 3Q 2022). Net loss: US$5.23m (loss narrowed 38% from 3Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 03Goodness Growth Holdings, Inc. to Report Q3, 2023 Results on Nov 14, 2023Goodness Growth Holdings, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
お知らせ • Sep 28Goodness Growth Holdings, Inc. Announces CFO ChangesGoodness Growth Holdings, Inc. announced that Chief Financial Officer, John Heller, will depart the Company effective September 30 to accept a new external opportunity. Interim Chief Executive Officer Josh Rosen will assume the additional role of Interim Chief Financial Officer.
New Risk • Aug 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$7.9m). Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CA$25.4m market cap, or US$18.9m).
Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.084 loss per share (vs US$0.048 loss in 2Q 2022)Second quarter 2023 results: US$0.084 loss per share (further deteriorated from US$0.048 loss in 2Q 2022). Revenue: US$20.2m (down 4.2% from 2Q 2022). Net loss: US$7.33m (loss widened 19% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
お知らせ • Aug 01Goodness Growth Holdings, Inc. to Report Q2, 2023 Results on Aug 14, 2023Goodness Growth Holdings, Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023
New Risk • Jul 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-US$2.1m). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (CA$27.8m market cap, or US$21.1m).
Reported Earnings • May 17First quarter 2023 earnings released: US$0.066 loss per share (vs US$0.11 loss in 1Q 2022)First quarter 2023 results: US$0.066 loss per share (improved from US$0.11 loss in 1Q 2022). Revenue: US$19.1m (up 22% from 1Q 2022). Net loss: US$8.41m (loss narrowed 42% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • May 10Goodness Growth Holdings, Inc. to Report Q1, 2023 Results on May 15, 2023Goodness Growth Holdings, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023
お知らせ • Feb 15+ 1 more updateGoodness Growth Holdings, Inc. Announces Management ChangesGoodness Growth Holdings, Inc. announced that Company founder, Dr. Kyle Kingsley, will assume the role of Executive Chairman. Chief Administrative Officer Amber Shimpa has been promoted to the role of President of the Company.
Price Target Changed • Jan 13Price target decreased to CA$0.85Down from CA$1.00, the current price target is provided by 1 analyst. New target price is 270% above last closing price of CA$0.23. The company posted a net loss per share of US$0.27 last year.
お知らせ • Dec 10Goodness Growth Holdings, Inc. Announces Departure of Christian Gonzalez-Ocasio as Chief Operating OfficerGoodness Growth Holdings, Inc. announced the departure of Chief Operating Officer, Christian Gonzalez-Ocasio. The Company intends to engage Mr. Gonzalez as a consultant for an interim period to help ensure a smooth transition with the Company's leadership team. Mr. Gonzalez had been serving as Chief Operating Officer of the Company since November 2020. He previously served as Executive Vice President of Operations, supporting manufacturing and retail initiatives, beginning in October 2019. The Company does not plan to immediately seek a replacement for the Chief Operating Officer position. Responsibilities of the position will be filled by a mix of existing internal resources.
お知らせ • Dec 06Goodness Growth Holdings, Inc Appoints Josh Rosen to the Role of Interim PresidentGoodness Growth Holdings, Inc. announced that it has appointed Josh Rosen to the role of Interim President, effective immediately. Mr. Rosen has been serving as a director of the Company since August 2021. While he will continue to serve on the Company's board of directors, his position as Interim President will significantly expand his roles and responsibilities. Mr. Rosen's new roles and responsibilities will focus on driving operational efficiencies and adult-use preparedness in the Company's various operating markets to better align resources to capitalize on the growing adoption of adult-use regulations and managing the Company's key capital and strategic relationships. Goodness Growth's C-Suite of executives will begin reporting directly to Mr. Rosen, effective immediately. Dr. Kyle Kingsley will continue in his role as Chairman and Chief Executive Officer, with primary responsibilities focused on collaborating with Mr. Rosen on strategy, government relations and the Company's ongoing commitment to effective medical cannabis products. Mr. Rosen and Dr. Kingsley will both report directly to the Company's Board of Directors. Mr. Rosen also serves as Managing Partner at Bengal Capital, and was formerly Chief Executive Officer and Chairman of 4Front Ventures. At 4Front, Josh helped lead the transformation of a pioneering industry consulting firm into an operations-focused, multi-state operator, notably including the acquisition of Cannex Capital. Prior to 4Front, Josh gained private equity experience managing the investment portfolio for a large family office and worked extensively in the public markets as an equity analyst, primarily at the global investment bank, Credit Suisse.
お知らせ • Nov 11Goodness Growth Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022Goodness Growth Holdings, Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022
お知らせ • Oct 15Goodness Growth Holdings, Inc., Annual General Meeting, Nov 18, 2022Goodness Growth Holdings, Inc., Annual General Meeting, Nov 18, 2022.